

FORM PTO-1449  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE CITATION</b>  <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO. 2026-4124US1	SERIAL NO. 08/417,714
	APPLICANT Kawakami And Rosenberg	
	FILING DATE April 5, 1995	GROUP 1813

## PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
STM	5 2 6 2 1 7 7	11/16/93	Brown et al.			
↓	5 3 4 2 7 7 4	08/31/94	Boon et al.			

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
STM	0 6 6 8 3 5 0	08/23/95	EPO				
↓	3 3 4 1 3 6 7	05/24/84	GERMANY (DE)				
↓	2 1 3 3 5 4 3	08/25/84	GB				
↓	9 5 2 2 5 6 1	08/24/95	PCT				
↓	9 4 2 3 0 6 7	10/13/94	PCT				
↓	9 3 1 4 1 8 9	07/22/93	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

STM	Coulie, P.G. et al. (1993) "Genes coding for tumor antigens recognized by human cytolytic T-lymphocytes" <i>J. Immunotherap.</i> 14:104-109
↓	Coulie P.G. et al. "A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas". <i>J. Exp. Med.</i> (1994) 180:35-42
↓	Mareah, C.A. et al.: Cloning and expression of the gene for the melanoma associated ME20 antigen. <i>DNA and Cell Biology</i> , 1994; 13:87-95
↓	Cox, A.L., et al. "Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines" <i>Science</i> 1994; 264:716-719.
↓	Brichard, V., et al.: "The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas". <i>J. Exp. Med.</i> 1993; 178:489-495.
↓	Gaugler, B., et al. "Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes". <i>J. Exp. Med.</i> 1994; 179:921-930.

SM		Traversari, C., et al.: "A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E". <i>J. Exp. Med.</i> 1992; 176:1453-1457.
		Cellis, E., et al.: "Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptides epitopes". <i>Proc. Natl. Acad. Sci. U.S.A.</i> 1994; 91:2105-2109.
		Boon, T.: "Toward a genetic analysis of tumor rejection antigens". <i>Adv. Cancer Res.</i> 1992; 58:177-210.
		Kawakami, Y., et al.: T-cell recognition of human melanoma antigens. <i>J. Immunother.</i> 1993; 14:88-93.
		Bakker, A.B.H., et al.: Melanocyte lineage-specific antigen gp100 is recognized by melanocyte-derived tumor infiltrating lymphocytes. <i>J. Exp. Med.</i> 1994; 179:1005-1009.
		Wölfel, T., et al.: Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. <i>Eur. J. Immunol.</i> 1994; 24:759-764.
		Adema, G.J., et al.: Melanocyte lineage-specific antigens recognized by monoclonal antibodies NK1-beteb, HMB-50, and HMB-45 are encoded by a single cDNA. <i>Am J. Pathol.</i> 1993; 143:1579-1585.
		Kwon, B.S., et al.: A melanocyte-specific gene, Pmel 17, maps near the silver coat color locus on mouse chromosome 10 and is in a syntenic region on human chromosome 12. <i>Proc. Natl. Acad. Sci. USA</i> 1991; 88:9228-9232.
		Rosenberg, S.A., et al.: Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. <i>N. Engl. J. Med.</i> 1988; 319:1676-1680.
		Kawakami, Y., et al.: Shared human melanoma antigens. Recognition by tumor infiltrating lymphocytes in HLA-A2.1 transfected melanomas. <i>J Immunol</i> 1992; 148:638-643.
		Van der Bruggen, et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. <i>Science</i> 1991; 254:1643-1647.
		Falk, K., et al.: "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules." <i>Nature</i> 1991, 351:290-296.
		Kubo, R., et al.: "Definition of specific peptide motifs for four major HLA-A Alleles." <i>Journal of Immunology</i> 1994, 152:3913-3924.
		Parker, K., et al.: "Sequence motifs important for peptide binding to the human MHC class I molecule. HLA-A2." 1992, <i>J. Immunol</i> :3580-3587.
		Ruppert, J., et al.: "Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules." <i>Cell</i> 1993, 74:929-937.
		Storkus, W., et al.: "Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes." <i>Journal of Immunology</i> 1993, 151:3719-3727.
		Kawakami, Y., et al.: "Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor." <i>Pro. Natl. Acad. Sci. USA</i> 1994, 91:3515-3519.
		Adema, G.J. et al., "Molecular characterization of the melanocyte lineage-specific antigen gp100." <i>Journal of Biological Chemistry</i> 1994, 269:20126-20133.
		EMBL DATABASE ACCESSION NUMBER M32295:26-11-90 Vogel A.: Human KD melanocyte specific secreted glycoprotein mRNA 3'end' (1990)
		Kawakami, Y., et al., "Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with <i>in vivo</i> tumor rejection" <i>PNAS</i> 91:6458-6462 1994
		Kawakami, Y., et al., "Identification of the Immunodominant Peptides of the MART-1 Human Melanoma Antigen Recognized by the Majority of HLA-A2-restricted Tumor Infiltrating Lymphocytes" <i>J. Exp. Med.</i> 180:347-352, 1994
		Rivoltini, L., et al., "Induction of Tumor-Reactive CTL from Peripheral Blood and Tumor-Infiltrating Lymphocytes of Melanoma Patients by In Vitro Stimulation with an Immunodominant Peptide of the Human Melanoma Antigen MART-1" <i>Journal of Immunology</i> , 1995, 154:2257-2265
		Slingluff, C.L., Jr., et al., "Direct analysis of tumor-associated peptide antigens" <i>Current Opinion in Immunology</i> 1994, 6:733-740

Shung

6/14/00

554		Cole, D.J., et al., "Characterization of the Functional Specificity of a Cloned T-Cell Receptor Heterodimer Recognizing the MART-1 Melanoma Antigen" <i>Cancer Res.</i> 55:748-752 Feb. 1995
		Cole, D.J., et al., "Identification of MART-1-specific T-Cell Receptors: T Cells Utilizing Distinct T-Cell Receptor Variable and Joining Regions Recognize the Same Tumor Epitope" <i>Cancer Res.</i> 54:5265-5268, 1994
		Castelli, C., et al., "Mass Spectrometric Identification of a Naturally Processed Melanoma Peptide Recognized by CD8 <sup>+</sup> Cytotoxic T Lymphocytes" <i>J. Exp. Med.</i> 181:363-368 1995
		Sette, A., et al., "Peptide Binding To The Most Frequent HLA-A Class I Alleles Measured By Quantitative Molecular Binding Assays" <i>Molecular Immunology</i> 31:813-822, 1994
		Wölfel, T., et al., "Analysis Of Antigens Recognized On Human Melanoma Cells By A2-Restricted Cytolytic T Lymphocytes (CTL)" <i>Int. J. Cancer</i> 55:237-244, 1993.
		Wölfel, T., et al., "Isolation Of Naturally Processed Peptides Recognized By Cytolytic Lymphocytes (CTL) On Human Melanoma Cells In Association With HLA-A2.1" <i>Int. J. Cancer</i> 57:413-418, 1994.
		Topalian, S.L., et al., "Human CD4 <sup>+</sup> T Cells Specifically Recognize a Shared Melanoma-Associated Antigen Encoded by the Tyrosinase Gene" <i>PNAS</i> 91:9461-9465, 1994.
		Boël, P., et al., "BAGE: a New Gene Encoding an Antigen Recognized on Human Melanomas by Cytolytic T Lymphocytes" <i>Immunity</i> 2:167-175 1995
		Slingluff, C.L., Jr., et al., "Recognition of Human Melanoma Cells by HLA-A2.1-Restricted Cytotoxic T Lymphocytes Is Mediated by at Least Six Shared Peptide Epitopes" <i>Journal of Immunology</i> 150:2955-2963 1993
		GENBANK DATABASE ACCESSION NUMBER M77348 - Human PMEL 17 in RNA - January 8, 1995
		GENBANK DATABASE ACCESSION NUMBER U06654 - Human Differentiation Antigen Melan-A Protein in RNA - July 30, 1994
		GENBANK DATABASE ACCESSION NUMBER U06452 - Human Melanoma Antigen Recognized by T-Cells (MAR7-1) MRNA - June 25, 1994
		GENBANK DATABASE ACCESSION NUMBER S73003 - GP100 Melanocyte Lineage Specific Antigen / PMEL 7 January 25, 1995
		GENBANK DATABASE ACCESSION NUMBER U01874 - Human ME20 MRNA May 27, 1994

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.